Introduction
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most debilitating side effects for patients undergoing cancer treatment. Beyond the physical discomfort, CINV significantly diminishes quality of life (QoL) and can lead to treatment non-adherence. While international guidelines recommend a "triple therapy" consisting of a 5-hydroxytryptamine (5-HT3) receptor antagonist, a glucocorticoid, and a neurokinin-1 (NK-1) receptor antagonist, the high cost of NK-1 antagonists presents a significant barrier to care in many regions.
In countries like China, NK-1 antagonists are often not covered by medical insurance, making the standard-of-care regimen financially inaccessible for many. This protocol outlines a multicenter, double-blind, randomized controlled trial (RCT) designed to evaluate the efficacy of olanzapine—an affordable atypical antipsychotic—as a substitute for NK-1 antagonists in a triple-drug antiemetic regimen for lung cancer patients.
Methodology
The study is designed as a multicenter, double-blind, randomized controlled trial involving 156 participants across several clinical sites in China.
Participant Selection
The trial targets patients aged 18–70 with histologically confirmed lung cancer (including adenocarcinoma, squamous cell, and small-cell histologies) who are scheduled to receive moderately to highly emetogenic chemotherapy.
Treatment Regimen
Participants are randomized 1:1 into two treatment arms:
- Experimental Group: Olanzapine (10 mg/day, days 1–4) combined with Dexamethasone (10 mg/day, days 1–3) and Tropisetron (4 mg/day, days 1–3).
- Comparator Group: A placebo (days 1–4) combined with the same doses of Dexamethasone and Tropisetron.
Both patients and physicians are blinded to the treatment allocation to ensure the integrity of the results.
Endpoints and Data Management
The primary objective is to assess the incidence of delayed CINV, defined as nausea or vomiting occurring between 24 and 120 hours post-chemotherapy. Secondary endpoints include:
- Complete response (CR) of acute CINV (0–24 hours).
- Complete response (CR) of delayed CINV.
- Effective control rate (ECR) of CINV.
- Patient Quality of Life (QoL).
Data collection utilizes an Electronic Data Capture (EDC) system. Quality of life is assessed through several validated instruments, including the EORTC QLQ-C30, the lung cancer-specific EORTC QLQ-LC13, the FACT-L, and the FLIE questionnaire.
Key Insights
Pharmacological Synergy
An interesting aspect of this regimen is the potential for side-effect synergy. Olanzapine is known to cause lethargy, which may help mitigate the insomnia and agitation frequently induced by dexamethasone, potentially improving the overall patient experience.
Healthcare Equity and Drug Repurposing
The study emphasizes the strategic repurposing of olanzapine to address socioeconomic disparities. By validating a lower-cost alternative to expensive NK-1 antagonists, the researchers aim to establish a more equitable standard of care that remains effective in resource-constrained settings.
Statistical Power and Expected Results
As a protocol, the paper focuses on the design's statistical validity. The sample size of 156 patients (78 per arm) was calculated to provide a Type II error rate of approximately 0.10. Based on existing literature, the researchers anticipate a control rate for delayed CINV of approximately 68% in the olanzapine group, compared to 40% in the placebo-controlled group.
Limitations
The authors identify several limitations inherent in the study design:
- Subjectivity: QoL assessments rely on self-reported questionnaires, which are subject to patient bias.
- Blinding Constraints: While clinical staff and patients are blinded, the researchers performing the final data analysis are not, which could influence interpretation.
- Scope: The trial currently only evaluates a single cycle of chemotherapy; the cumulative effects over multiple cycles remain a subject for future investigation.
- Economic Analysis: While the study is motivated by cost-effectiveness, a formal pharmacoeconomic analysis is not part of this specific protocol.
Conclusion
This trial represents a critical step toward optimizing antiemetic therapy for lung cancer patients. If successful, it will provide robust evidence for an affordable, triple-drug regimen that maintains high efficacy without the financial burden of NK-1 receptor antagonists.
Summary updated